Okay.
We do a few things. I've already mentioned the priority review process, where we think something has a really significant opportunity to contribute to health care and health outcomes for Canadians. We also approve generic products. We do this in a way that respects the patent requirements and market exclusivity for brand-name products. Generic products, in general, are much lower cost versions of the products that innovators have developed.